Successful conduct of an acute stroke clinical trial during COVID.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 29 10 2020
accepted: 24 11 2020
entrez: 15 1 2021
pubmed: 16 1 2021
medline: 22 4 2021
Statut: epublish

Résumé

Most clinical research stopped during COVID due to possible impact on data quality and personnel safety. We aimed to assess the impact of COVID on acute stroke clinical trial conduct at sites that continued to enroll patients during the pandemic. BEST-MSU is an ongoing study of Mobile Stroke Units (MSU) vs standard management of tPA-eligible acute stroke patients in the pre-hospital setting. MSU personnel include a vascular neurologist via telemedicine, and a nurse, CT technologist, paramedics and emergency medicine technicians on-board. During COVID, consent, 90-day modified Rankin Scale (mRS) and EQ5D were obtained by phone instead of in-person, but other aspects of management were similar to the pre-COVID period. We compared patient demographics, study metrics, and infection of study personnel during intra- vs pre-COVID eras. Five of 6 BEST-MSU sites continued to enroll during COVID. There were no differences in intra- (n = 57) vs pre- (n = 869) COVID enrolled tPA eligible patients' age, sex, race (38.6% vs 38.0% Black), ethnicity (15.8% vs 18.6% Hispanic), or NIHSS (median 11 vs 9). The percent of screened patients enrolled and adjudicated tPA eligible declined from 13.6% to 6.6% (p < .001); study enrollment correlated with local stay-at-home and reopening orders. There were no differences in alert to MSU arrival or arrival to tPA times, but MSU on-scene time was 5 min longer (p = .01). There were no differences in ED door to CT, tPA treatment or thrombectomy puncture times, hospital length of stay, discharge disposition, or remote vs in-person 90-day mRS or EQ5D. One MSU nurse tested positive but did not require hospitalization. Clinical research in the pre-hospital setting can be carried out accurately and safely during a pandemic. tPA eligibility rates declined, but otherwise there were no differences in patient demographics, deterioration of study processes, or serious infection of study staff. Trial registration: NCT02190500.

Identifiants

pubmed: 33449944
doi: 10.1371/journal.pone.0243603
pii: PONE-D-20-34076
pmc: PMC7810330
doi:

Substances chimiques

Tissue Plasminogen Activator EC 3.4.21.68

Banques de données

ClinicalTrials.gov
['NCT02190500']

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0243603

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Stroke Cerebrovasc Dis. 2020 Oct;29(10):105114
pubmed: 32912527
Stroke. 2017 Feb;48(2):493-496
pubmed: 28082671
Trials. 2020 Sep 11;21(1):784
pubmed: 32917258
Neurol Int. 2013 Feb 19;5(1):e2
pubmed: 23717781
Int J Stroke. 2018 Apr;13(3):321-327
pubmed: 28612680
Nat Rev Cardiol. 2020 Nov;17(11):673-675
pubmed: 32873977
Stroke. 2018 Jun;49(6):1528-1530
pubmed: 29720439
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
Restor Neurol Neurosci. 2015;33(5):771-5
pubmed: 26410209
Stroke. 2020 Sep;51(9):2664-2673
pubmed: 32755347

Auteurs

Jose-Miguel Yamal (JM)

Department of Biostatistics and Data Science, UTHealth School of Public Health, Houston, Texas, United States of America.

Stephanie A Parker (SA)

Department of Neurology, UTHealth, Houston, Texas, United States of America.

Asha P Jacob (AP)

Department of Biostatistics and Data Science, UTHealth School of Public Health, Houston, Texas, United States of America.

Suja S Rajan (SS)

Department of Management, Policy & Community Health, UTHealth School of Public Health, Houston, Texas, United States of America.

Ritvij Bowry (R)

Department of Neurology, UTHealth, Houston, Texas, United States of America.

Patti Bratina (P)

Department of Neurology, UTHealth, Houston, Texas, United States of America.

Mengxi Wang (M)

Department of Biostatistics and Data Science, UTHealth School of Public Health, Houston, Texas, United States of America.

May Nour (M)

Departments of Neurology-Radiology, UCLA, Los Angeles, California, United States of America.

Jason Mackey (J)

Department of Neurology, Indiana University, Indianapolis, Indiana, United States of America.

Sarah Collins (S)

Indiana University Health, Fishers, Indiana, United States of America.

William Jones (W)

Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.

Brandi Schimpf (B)

Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.

David Ornelas (D)

UCHealth, Morrison, Colorado, United States of America.

Ilana Spokoyny (I)

Sutter Health, Burlingame, California, United States of America.

Jenny Fung Im (JF)

Department of Neuroscience and Orthopedic Service, Mills Peninsula Medical Center, Burlingame, California, United States of America.

Greg Gilbert (G)

Emergency Medical System San Mateo County, California, United States of America.

Michael Eisshofer (M)

Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.

James C Grotta (JC)

Clinical Innovation and Research Institute, Memorial Hermann Hospital, Houston, Texas, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH